Helix BioPharma Corp. (HBPCF) Stock

About Helix BioPharma Corp.

Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology. The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to interact with vascular epithelial growth factor receptor 2 (VEGFR2). Helix has established collaborative agreements to further its research. One such partnership with Moffitt Cancer Center involves studying L-DOS47's pharmacodynamics and exploring the advantages of co-administering it with immune checkpoint inhibitors. A separate collaboration with University Hospital Tuebingen focuses on evaluating L-DOS47's therapeutic impact on CEACAM6-positive cancer models, employing advanced preclinical metabolic imaging techniques. The company's corporate headquarters are located in Toronto, Canada.

Helix BioPharma Corp. is headquartered in CA.

Helix BioPharma Corp. (HBPCF) stock trades at $1.71 with a market capitalization of $130.61M. The stock is valued at a negative price-to-earnings (P/E) ratio of -32.27, reflecting a net loss over the last twelve months, price-to-book of 7.38, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.60 and $1.73, and currently trades 1.2% below its 52-week high.

On profitability, Helix BioPharma Corp. generates a return on equity (ROE) of -21.54% (negative, reflecting a net loss), return on capital employed of -22.47%.

Official website: www.helixbiopharma.com